Literature DB >> 16960112

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene.

Giuseppe Del Giudice1, Elena Fragapane, Roberto Bugarini, Maninder Hora, Thomas Henriksson, Emanuela Palla, Derek O'hagan, John Donnelly, Rino Rappuoli, Audino Podda.   

Abstract

Squalene is a naturally occurring oil which has been used in the development of vaccine adjuvants, such as the oil-in-water emulsion MF59. In past years, by use of noncontrolled and nonvalidated assays, a claim was made that antisqualene antibodies were detectable in the sera of individuals with the so-called Gulf War syndrome. Using a validated enzyme-linked immunosorbent assay for the quantitation of immunoglobulin G (IgG) and IgM antibodies against squalene, we demonstrated that antisqualene antibodies are frequently detectable at very low titers in the sera of subjects who were never immunized with vaccines containing squalene. More importantly, vaccination with a subunit influenza vaccine with the MF59 adjuvant neither induced antisqualene antibodies nor enhanced preexisting antisqualene antibody titers. In conclusion, antisqualene antibodies are not increased by immunization with vaccines with the MF59 adjuvant. These data extend the safety profile of the MF59 emulsion adjuvant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960112      PMCID: PMC1563566          DOI: 10.1128/CVI.00191-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  14 in total

Review 1.  Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism.

Authors:  C R Alving; N M Wassef
Journal:  Immunol Today       Date:  1999-08

2.  Re: Antibodies to squalene in Gulf War Syndrome.

Authors:  C R Alving; J D Grabenstein
Journal:  Exp Mol Pathol       Date:  2000-06       Impact factor: 3.362

3.  Antibodies to squalene in Gulf War syndrome.

Authors:  P B Asa; Y Cao; R F Garry
Journal:  Exp Mol Pathol       Date:  2000-02       Impact factor: 3.362

4.  Induction and detection of antibodies to squalene.

Authors:  G R Matyas; N M Wassef; M Rao; C R Alving
Journal:  J Immunol Methods       Date:  2000-11-01       Impact factor: 2.303

Review 5.  War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War.

Authors:  K C Hyams; F S Wignall; R Roswell
Journal:  Ann Intern Med       Date:  1996-09-01       Impact factor: 25.391

6.  Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice.

Authors:  Gary R Matyas; Mangala Rao; Phillip R Pittman; Robert Burge; Iris E Robbins; Nabila M Wassef; Brandie Thivierge; Carl R Alving
Journal:  J Immunol Methods       Date:  2004-03       Impact factor: 2.303

7.  Antibodies to squalene in recipients of anthrax vaccine.

Authors:  Pamela B Asa; Russell B Wilson; Robert F Garry
Journal:  Exp Mol Pathol       Date:  2002-08       Impact factor: 3.362

Review 8.  MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.

Authors:  Audino Podda; Giuseppe Del Giudice
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

9.  Antibodies to cholesterol.

Authors:  G M Swartz; M K Gentry; L M Amende; E J Blanchette-Mackie; C R Alving
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins.

Authors:  T A Miettinen
Journal:  J Lipid Res       Date:  1982-03       Impact factor: 5.922

View more
  17 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

3.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

Review 4.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

6.  Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.

Authors:  Ming-Hsi Huang; Su-Chen Lin; Chia-Hsin Hsiao; Hsin-Ju Chao; Hung-Ren Yang; Chien-Chun Liao; Po-Wei Chuang; Huang-Pi Wu; Chiung-Yi Huang; Chih-Hsiang Leng; Shih-Jen Liu; Hsin-Wei Chen; Ai-Hsiang Chou; Alan Yung-Chih Hu; Pele Chong
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

7.  Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.

Authors:  Heather L Forrest; Alexey M Khalenkov; Elena A Govorkova; Jeong-Ki Kim; Giuseppe Del Giudice; Robert G Webster
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641

Review 8.  AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Authors:  Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

Review 9.  Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.

Authors:  Huub F J Savelkoul; Valerie A Ferro; Marius M Strioga; Virgil E J C Schijns
Journal:  Vaccines (Basel)       Date:  2015-03-05

Review 10.  MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Authors:  Angelika Banzhoff; Michele Pellegrini; Giuseppe Del Giudice; Elena Fragapane; Nicola Groth; Audino Podda
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.